Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.47 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30987223 | 0.75 | MAPT (0.60) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL28563540 | 0.75 | MAPT (0.60) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL11654916 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL291121 | 0.71 | KDM4E (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL329419 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL12329 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL4204967 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL446289 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL3810651 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL290849 | 0.71 | KDM4E (1.00) | MAPTKDM4EALDH1A1HSD17B10EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276524-B2 | Pyridyl alkane acid amides as cytostatics and immunosuppressives | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-10-02 | — | — | US | claimed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | claimed |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | BIEDERMANN ELFI | 2007-06-21 | — | — | US | claimed |
| US-20040176605-A1 | New pyridyl alkane acid amides as cytostatics and immunosuppressives | KLINGE PHARMA GMBH | 2004-09-09 | — | — | US | claimed |
| US-20040029861-A1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | KLINGE PHARMA GMBH | 2004-02-12 | — | — | US | claimed |
| US-20040009967-A1 | Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | KLINGE PHARMA GMBH | 2004-01-15 | — | — | US | claimed |
| US-20030162972-A1 | Pyridyl alkane acid amides as cytostatics and immunosupressives | KLINGE PHARMA GMBH | 2003-08-28 | — | — | US | claimed |
| EP-0866148-B1 | Method for inhibiting corrosion in water systems | KURITA WATER IND LTD (JP) | 2001-09-19 | — | — | EP | claimed |
| JP-2000512652-A | — | — | 2000-09-26 | — | — | JP | claimed |
| EP-0934309-A1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | Klinge Pharma GmbH (DE) | 1999-08-11 | — | — | EP | claimed |
| EP-0923570-A1 | PYRIDYL ALKENE- AND PYRIDYL ALKINE- ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | Klinge Pharma GmbH (DE) | 1999-06-23 | — | — | EP | claimed |
| EP-0912176-A1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | Klinge Pharma GmbH (DE) | 1999-05-06 | — | — | EP | claimed |
| WO-1997048696-A1 | PYRIDYL ALKENE- AND PYRIDYL ALKINE- ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | KLINGE PHARMA GMBH (DE) | 1997-12-24 | — | — | WO | claimed |
| WO-1997048397-A1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | KLINGE PHARMA GMBH (DE) | 1997-12-24 | — | — | WO | claimed |
| WO-1997048695-A1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | KLINGE PHARMA GMBH (DE) | 1997-12-24 | — | — | WO | claimed |
| EP-0530136-B1 | Nematicidal agents | CIBA GEIGY AG (CH) | 1996-02-21 | — | — | EP | claimed |
| EP-0530136-A2 | Nematicidal agents | CIBA-GEIGY AG (CH) | 1993-03-03 | — | — | EP | claimed |
| US-4242495-A | COATINGS, MOLDINGS, FOAMS | THE FIRESTONE TIRE & RUBBER COMPANY (US) | 1980-12-30 | — | — | US | claimed |
| CN-119744874-A | Solvent for dissolving benziothiazolinone and application thereof | 陕西西大华特科技实业有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-4168317-A | CARDIOVASCULAR DISORDERS, ANTIARRYTHMIA | BASF AKTIENGESELLSCHAFT (DE) | 1979-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176605-A1 | New pyridyl alkane acid amides as cytostatics and immunosuppressives | ALK, ANXA1, ANXA11 | MAPT 3852/4885KDM4E 2249/4885ALDH1A1 216/4885 |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | NFATC1, PDCD1, ACIN1 | MAPT 4047/4885KDM4E 1717/4885ALDH1A1 690/4885 |
| US-20040009967-A1 | Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | IDO1, ALK, ARG1 | MAPT 4119/4885KDM4E 1627/4885ALDH1A1 173/4885 |
| US-20040029861-A1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | ALK, IDO1, PDXK | MAPT 4351/4885KDM4E 1569/4885ALDH1A1 113/4885 |
| US-20030162972-A1 | Pyridyl alkane acid amides as cytostatics and immunosupressives | ALK, TYMP, ANXA1 | MAPT 3593/4885KDM4E 2193/4885ALDH1A1 168/4885 |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | ALK, TYMP, PDCD1 | MAPT 3831/4885KDM4E 2336/4885ALDH1A1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.